#1 Clinical Trials Search in Europe

Ganaxolone

Ganaxolone is an investigational drug being studied in clinical trials for its potential to treat various forms of epilepsy and related neurological disorders. This article explores the ongoing research into ganaxolone’s effectiveness and safety for conditions like drug-resistant epilepsy, infantile spasms, and tuberous sclerosis complex. We’ll examine key findings from recent clinical trials to understand how this medication may benefit patients with difficult-to-treat seizure disorders.

Table of Contents

What is Ganaxolone?

Ganaxolone is a medication that belongs to a class of drugs known as neuroactive steroids. It is an analog of allopregnanolone, which is a naturally occurring hormone in the human body[1]. Ganaxolone is also known by other names such as CCD 1042 and 3 alpha-hydroxy, 3 beta-methyl, 5 alpha-pregnan-20-one[2]. This medication is being studied and used primarily for its potential in treating various forms of epilepsy and other neurological disorders.

What Conditions Does Ganaxolone Treat?

Ganaxolone is being investigated and used to treat several conditions, including:

  • Epilepsy: Particularly for patients with drug-resistant partial-onset seizures[3]
  • PCDH19-Related Epilepsy: A rare genetic disorder that causes seizures primarily in females[4]
  • Tuberous Sclerosis Complex (TSC): A genetic disorder that causes benign tumors to grow in various parts of the body, often leading to seizures[5]
  • Infantile Spasms: A rare seizure disorder that occurs in young children[6]
  • CDKL5 Deficiency Disorder: A rare genetic condition that causes seizures and developmental delays[7]
  • Treatment-Resistant Depression: As a potential augmentation therapy[1]

How Does Ganaxolone Work?

Ganaxolone works by modulating the activity of GABA-A receptors in the brain. GABA (gamma-aminobutyric acid) is a neurotransmitter that helps to calm brain activity. By enhancing the effects of GABA, ganaxolone may help to reduce excessive brain activity that can lead to seizures or other neurological symptoms[1]. This mechanism of action is similar to that of naturally occurring allopregnanolone in the body, which is known to have positive effects on mood and neurological function.

How is Ganaxolone Administered?

Ganaxolone is typically administered in the following forms:

  • Oral suspension: A liquid form that is taken by mouth, usually three times a day[5]
  • Capsules: Solid form taken orally, often multiple times per day[3]

The dosage and frequency of administration may vary depending on the specific condition being treated, the patient’s age, and other individual factors. It’s important to follow the prescribing doctor’s instructions carefully.

Clinical Trials and Research

Ganaxolone has been and continues to be studied in various clinical trials for different conditions:

  • For PCDH19-Related Epilepsy: The Violet Study is investigating ganaxolone’s effectiveness in reducing seizures in female children and young adults with this rare genetic disorder[4].
  • For Tuberous Sclerosis Complex: Studies are examining ganaxolone’s potential in reducing seizures associated with TSC[5].
  • For Treatment-Resistant Depression: Research is exploring ganaxolone as a potential augmentation therapy for women who haven’t responded to standard antidepressant treatments[1].
  • For Infantile Spasms: Clinical trials have investigated ganaxolone’s safety and effectiveness in treating this rare seizure disorder in infants[6].

Potential Side Effects

As with any medication, ganaxolone may cause side effects. Common side effects reported in clinical trials include:

  • Drowsiness or fatigue
  • Dizziness
  • Headache
  • Nausea

More serious side effects may occur, but are less common. It’s important to discuss potential side effects with your healthcare provider and report any unusual symptoms you experience while taking ganaxolone[5].

Important Considerations for Patients

If you’re considering or currently taking ganaxolone, keep these points in mind:

  • Ganaxolone is often used as an add-on therapy, meaning it’s taken in addition to other anti-seizure medications[3].
  • Regular check-ups and monitoring may be required to assess the medication’s effectiveness and any potential side effects[5].
  • The full effects of ganaxolone may take several weeks to become apparent, so patience is important when starting this medication.
  • Never stop taking ganaxolone abruptly without consulting your doctor, as this could lead to an increase in seizures or other symptoms.
  • Inform your healthcare provider about all other medications you’re taking, as ganaxolone may interact with other drugs.

Remember, ganaxolone is a promising medication for several neurological conditions, but it’s important to work closely with your healthcare team to determine if it’s the right choice for your specific situation.

Aspect Details
Drug Name Ganaxolone
Conditions Studied Drug-resistant partial-onset seizures, PCDH19-related epilepsy, Infantile spasms, Tuberous sclerosis complex (TSC)-related epilepsy, CDKL5 deficiency disorder, Major depressive disorder
Administration Oral suspension or capsules, typically given multiple times per day
Primary Outcomes Reduction in seizure frequency, percent change from baseline in 28-day seizure frequency
Secondary Outcomes Responder rates (≥50% reduction in seizures), quality of life measures, global impression of change scores
Safety Monitoring Adverse events, vital signs, physical and neurological examinations, laboratory tests
Trial Designs Double-blind placebo-controlled, open-label extension studies, expanded access programs
Patient Populations Children, adolescents, and adults with various forms of epilepsy and related disorders

FAQ

  • What is ganaxolone? Ganaxolone is an investigational drug that is being studied as a potential treatment for various forms of epilepsy and related neurological disorders. It is a synthetic analog of allopregnanolone, a naturally occurring neurosteroid in the brain.
  • What conditions is ganaxolone being studied for? Ganaxolone is being investigated for several conditions, including drug-resistant partial-onset seizures, PCDH19-related epilepsy, infantile spasms, tuberous sclerosis complex (TSC)-related epilepsy, and CDKL5 deficiency disorder.
  • How is ganaxolone administered in clinical trials? In most clinical trials, ganaxolone is administered orally, either as a liquid suspension or in capsule form. The dosage and frequency vary depending on the specific study and condition being treated, but it is often given multiple times per day.
  • What are the primary outcomes being measured in ganaxolone trials? The primary outcomes in most ganaxolone trials focus on the reduction in seizure frequency. Researchers typically measure the percent change from baseline in 28-day seizure frequency and the proportion of patients achieving a 50% or greater reduction in seizures.
  • Are there any known side effects of ganaxolone? While the full safety profile is still being established through clinical trials, researchers are monitoring for adverse events, changes in vital signs, and abnormalities in physical and neurological examinations. The specific side effects can vary depending on the patient population and dosage used in each study.

Ongoing Clinical Trials on Ganaxolone

  • Study on Ganaxolone for Children and Adults with Epilepsy Related to Tuberous Sclerosis Complex

    Not recruiting

    1 1 1
    Investigated drugs:
    Belgium France Germany Italy Spain

  • Study on Ganaxolone for Patients with Refractory Status Epilepticus

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Croatia Czechia Denmark Finland +8

Glossary

  • Epilepsy: A neurological disorder characterized by recurrent seizures, which are sudden, uncontrolled electrical disturbances in the brain.
  • Seizure: A sudden, uncontrolled electrical disturbance in the brain that can cause changes in behavior, movements, feelings, and consciousness.
  • Drug-resistant epilepsy: A form of epilepsy where seizures are not controlled by two or more appropriately chosen and tolerated anti-seizure medications.
  • Tuberous Sclerosis Complex (TSC): A rare genetic disorder that causes non-cancerous tumors to grow in various organs, often leading to epilepsy and other neurological symptoms.
  • PCDH19-related epilepsy: A rare form of epilepsy caused by mutations in the PCDH19 gene, primarily affecting females and characterized by clusters of seizures.
  • Infantile spasms: A rare but serious type of seizure disorder that occurs in young children, typically before one year of age.
  • Open-label study: A type of clinical trial where both the researchers and participants know which treatment is being administered.
  • Placebo: An inactive substance that looks like the drug being tested but has no medical effect, used as a control in clinical trials.
  • Adjunctive therapy: An additional treatment used together with the primary treatment to increase its effectiveness.
  • Baseline: The initial measurement taken before a treatment or intervention begins, used as a point of comparison for subsequent measurements.

References

  1. https://clinicaltrials.gov/study/NCT02900092
  2. https://clinicaltrials.gov/study/NCT01002820
  3. https://clinicaltrials.gov/study/NCT02519439
  4. https://clinicaltrials.gov/study/NCT03865732
  5. https://clinicaltrials.eu/trial/study-on-ganaxolone-for-children-and-adults-with-epilepsy-related-to-tuberous-sclerosis-complex/
  6. https://clinicaltrials.gov/study/NCT00442104
  7. https://clinicaltrials.gov/study/NCT04678479